Friday, October 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 19, 2026

Next-Level Creators, Top Media Leaders, Storytelling Legends and AI Step Into the Spotlight As 2026 NAB Show Unveils Latest Speakers, Sessions

View original at globenewswire.com
Next-Level Creators, Top Media Leaders, Storytelling Legends and AI Step Into the Spotlight As 2026 NAB Show Unveils Latest Speakers, Sessions Washington, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- Washington, D.C.— The 2026 NAB Show, taking place April 18–22 (exhibits April 19–22) at the Las Vegas Convention Center, tod…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We're seeing a moment where technology, creativity and business are all evolving at the same time

    60% confidence

  • The 2026 NAB Show lineup is one that truly reflects where the industry is right now: a powerful mix of emerging creators and world-class storytellers alongside the technologies shaping how content is made and delivered

    60% confidence

  • We're seeing that same momentum in our registration, with a significant influx of new voices joining established leaders from across the global media ecosystem

    60% confidence

  • The 2026 NAB Show brings that entire ecosystem together to explore how those changes are shaping the future of storytelling

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com